Microneedling marketing rules: device, results and combination claims

Microneedling is sold by dermatology practices, med spas, plastic surgery offices and aesthetic clinics, often as a series of visits and often bundled with something else: radiofrequency energy, platelet-rich plasma (PRP) or a serum. Each of those details shows up in the marketing, and each one is a claim the clinic has to be able to support.

This guide covers what FDA has authorized microneedling devices for, how to describe your device, which add-on claims FDA has not reviewed, what FDA said about radiofrequency (RF) microneedling in 2025, and how the FTC Act applies to result claims, photos and testimonials. For device wording across all specialties, see our guide to medical device marketing claims. For PRP itself, see our guide to PRP injection clinic marketing. For chemical peel claims and take-home peel products, see our guide to chemical peel advertising rules.

The short version

• Know what your device was authorized for. FDA says it has authorized microneedling devices to improve the appearance of facial acne scars, facial wrinkles and abdominal scars in patients aged 22 or older. Claims outside your device’s authorized use are claims FDA has not reviewed.
• Say “FDA-cleared”, not “FDA-approved”, and only if it is true. Microneedling devices for aesthetic use are Class II devices subject to 510(k) (21 CFR 878.4430). 21 CFR 807.97 says a clearance does not denote official approval.
• Combination and hair loss claims are not cleared uses. FDA says it has not cleared any microneedling device for use with another product, such as PRP, creams or drugs, and has not cleared any for hair loss.
• RF microneedling carries an FDA safety communication. In October 2025 FDA reported serious complications, including burns, scarring, fat loss, disfigurement and nerve damage, with certain uses.
• Results need evidence. The FTC Act bars false advertisements for devices and services (15 USC 52), and a patient’s before-and-after is read as typical unless you say what patients generally get (16 CFR 255.2(b)).

What FDA has authorized microneedling devices for

21 CFR 878.4430 identifies a microneedling device for aesthetic use as “a device using one or more needles to mechanically puncture and injure skin tissue for aesthetic use.” It is Class II with special controls, and the classification “does not include devices intended for transdermal delivery of topical products such as cosmetics, drugs, or biologics.” FDA’s 2020 guidance adds that these devices reach the market through premarket notification (510(k)) and must meet the special controls in 878.4430(b)(1) to (10).

FDA’s Microneedling Devices page states the authorized uses: “to improve the appearance of facial acne scars, facial wrinkles, and abdominal scars in patients aged 22 years or older.” The same page says FDA “has only granted marketing authorization for a limited number of medical devices for specific uses in specified areas of the face and body,” and that the public 510(k) and De Novo summaries specify the intended areas for each device. FDA’s consumer update adds that FDA “has not authorized any microneedling medical devices for over-the-counter sale.”

For a clinic, the practical step is to look up your own device’s 510(k) summary (FDA’s page points to product code QAI) and match your service page to what it says. If the summary covers facial acne scars and facial wrinkles, a page that advertises microneedling for stretch marks, neck crepiness or scalp hair is describing uses outside that authorization.

Describing the device: cleared, approved and registered

21 CFR 807.97 says a 510(k) clearance “does not in any way denote official approval of the device,” and “any representation that creates an impression of official approval of a device because of complying with the premarket notification regulations is misleading and constitutes misbranding.” Registration of an establishment likewise “does not in any way denote approval of the establishment or its products” (21 CFR 807.39).

• Accurate if true: “We use an FDA-cleared microneedling device”, or “cleared by the FDA to improve the appearance of facial acne scars”, if your device’s clearance covers that use.
• Avoid: “FDA-approved microneedling”, “FDA-certified”, or an FDA logo next to your service.
• Avoid: “FDA-cleared” next to a treatment the clearance does not cover, such as a PRP add-on or a hair loss protocol.
• Avoid: “medical-grade” as a quality claim with no defined meaning behind it.

FDA’s guidance also explains why the words matter. In deciding whether a product is a device, FDA considers claims that it penetrates living layers of skin, and lists claims it believes would generally make a product a device, including “treats scars”, “treats wrinkles and deep facial lines”, “treats cellulite and stretch marks”, “treats acne”, “treats alopecia (hair loss)” and “stimulates collagen production.” That guidance is written for the firms responsible for a product’s labeling, not for clinics, but it shows how FDA reads those phrases: as claims about changing the structure or function of the body.

Combination claims: PRP, serums and hair loss

Microneedling is often advertised with something applied to the skin during or after the procedure. FDA’s position is direct. Its Microneedling Devices page says: “Microneedling devices are not approved for delivery of cosmetics, topical medications (for example, creams, ointments, gels), vitamin solutions, drugs, or blood products (for example, platelet-rich plasma (PRP)) into the skin.” Its consumer update says FDA “has not cleared any microneedling devices for use with another product, which means the FDA hasn’t reviewed the safety or effectiveness of combining microneedling devices with other products.” The same update says FDA has not cleared any microneedling device for hair loss.

FDA’s device page adds that “the risks associated with other uses (‘off label uses’) of microneedling devices, the combination of microneedling devices with other products, or the use of microneedling products that have not been evaluated by the FDA are not known.”

What follows for marketing:

• Do not attach “FDA-cleared” to a PRP microneedling package, a serum infusion or a hair restoration protocol. The device’s clearance does not cover the combination.
• Do not claim the add-on “drives” a product deeper, “boosts results by” a percentage or “doubles collagen” unless you have evidence for that exact claim (15 USC 52).
• If you offer a combination, describe what is done and say that FDA has not reviewed the combination. Leaving that out while implying it is an authorized treatment can be misleading by omission (15 USC 55(a)(1)).
• Hair loss pages that feature microneedling should not present it as an FDA-cleared hair treatment. See our guide to hair restoration clinic marketing.

RF microneedling: the 2025 FDA safety communication

On October 15, 2025, FDA issued a safety communication on radiofrequency microneedling. FDA said it “is aware of reports of serious complications (adverse events) including burns, scarring, fat loss, disfigurement, and nerve damage, and the need for surgical repair or medical intervention to treat injuries” with use of these devices for dermatologic or aesthetic procedures such as wrinkle treatment, resurfacing, “tightening” or “rejuvenation.” FDA said its evaluation is ongoing. It describes RF microneedling devices as Class II devices cleared through the 510(k) process, and states that “RF microneedling is a medical procedure, not a cosmetic treatment, and these devices should not be used at home.”

FDA’s recommendations to patients include seeking care from a licensed health care provider trained on the devices and asking which device will be used. For a clinic’s marketing, that suggests:

• Do not call RF microneedling “no downtime”, “zero risk”, “completely safe” or “a facial”. FDA’s own description is a medical procedure with reported serious complications.
• Name the device you use, or be ready to name it when patients ask, as FDA advises them to.
• State who performs the procedure and their training, accurately.
• Describe “tightening” and “rejuvenation” results only as far as your device’s cleared indication and your evidence allow.

Results, risks and session claims

15 USC 52(a) makes it unlawful to disseminate a false advertisement likely to induce the purchase of food, drugs, devices, services or cosmetics. Microneedling is a service performed with a device, so both parts of that list apply. 15 USC 55(a)(1) defines a false advertisement as one misleading in a material respect, including by failing to reveal facts that are material in light of what it does say.

FDA’s pages give a baseline for what patients should hear. They say microneedling procedures “may not always result in the desired aesthetic outcome”, that “you may need more than one procedure”, and, in the consumer update, that “any improvement in appearance may be temporary and maintenance may require additional procedures over time.” FDA lists common risks (dryness, rough skin, tightness, redness, itching, peeling, discomfort, burning, bruising, bleeding, crusting) and less common ones, including pigmentation changes, reactivation of cold sores, swollen lymph nodes and infection. FDA also notes that some devices it authorized “were not studied in subjects with darker skin types.”

Claims to avoid unless you have evidence that fits your device, your protocol and the patient shown:

• “Permanent results”, “one session is all you need” or a fixed session count stated as a promise.
• “No side effects”, “no downtime”, “painless” or “safe for all skin types”.
• “Erases acne scars” or “removes wrinkles” where the cleared wording is to improve their appearance.
• Percentages such as “up to 400% more collagen” with no study behind them that matches your device and protocol.

Accurate alternatives describe the process: that the number of sessions is set at a consultation, that results vary and may need maintenance, the common side effects, who is not a candidate, and who performs the treatment. Our guide to “clinically proven” and “doctor recommended” claims covers claims that cite studies.

Before-and-after photos and testimonials

Under 16 CFR 255.2(a), an ad using consumer endorsements about a product’s performance is read as saying the product works for the purpose shown, and the advertiser needs the same substantiation it would need to say it directly. Under 255.2(b), a result on a key attribute is likely read as what people will generally achieve; if you do not have evidence that it is, the ad should clearly and conspicuously disclose the generally expected performance in the circumstances shown, and you need evidence for that disclosure too.

• Use your own patients’ photos, taken with your device and protocol, with written permission; see our guides to testimonials and before-and-after photos and patient photo consent.
• Label each pair with the number of sessions, the time between photos and any add-on used, so a PRP combination result is not shown as a plain microneedling result.
• Use the same lighting, angle and distance, and do not edit the after photo beyond cropping.
• Do not use a device maker’s brochure photos as if they were your results.

Safety practices you can talk about

Patients read infection control as a reason to choose a clinic, and FDA gives clinics concrete points to describe truthfully. FDA tells providers to use only FDA-authorized devices and to check purchased devices against FDA’s 510(k) or De Novo databases, noting that it “is aware of several microneedling devices that are not legally marketed.” It tells patients to ask whether a new cartridge is used for each patient and each session, and says re-use of the needle cartridge “is unsafe and is not consistent with the FDA’s review and authorization, even if the cartridge is cleaned.”

If your clinic uses a new cartridge for every session, saying so is a fair, checkable claim. Do not say it unless it is your written practice and staff follow it.

Who performs the treatment

FDA recommends patients choose a provider trained in microneedling and ask about the provider’s training and experience. Rules on who may perform microneedling, and under what supervision, are set by each state, and we did not read them for this guide. Whatever your state allows, describe the operator’s role and training accurately: do not call staff “specialists” or “certified” unless that is true and you can say who certified them. Credentials are factual claims under 15 USC 52 like any other.

An illustration

This is a made-up example, not a client. A med spa’s microneedling page says “FDA-approved collagen induction”, “permanent results in one session”, “no downtime”, advertises “PRP microneedling, FDA-cleared” and “RF microneedling for hair regrowth”, and shows before-and-after photos from the device maker’s brochure.

The fix: the spa checks its device’s 510(k) summary and changes the headline to “FDA-cleared microneedling to improve the appearance of facial acne scars and wrinkles”, matching the cleared use (21 CFR 807.97). “Permanent” and “one session” go; the page now says sessions are set at consultation and results may need maintenance, as FDA’s pages describe. The PRP package stays but loses “FDA-cleared” and says FDA has not reviewed the combination. The hair regrowth line comes down, since FDA has not cleared microneedling for hair loss. The RF page drops “no downtime” and lists the risks FDA reported. The brochure photos are replaced by consented patient photos labeled with sessions and add-ons (16 CFR 255.2).

Checklist

• Service page matches your device’s cleared indication and body area (21 CFR 878.4430; your 510(k) summary).
• “FDA-cleared” only if true and for the use shown; never “FDA-approved” (21 CFR 807.97).
• No “FDA-cleared” next to PRP, serum, drug or hair loss combinations.
• RF microneedling pages reflect FDA’s October 2025 safety communication; no “no downtime” or “zero risk”.
• No promise of permanent results, a fixed session count, no side effects or suitability for all skin types.
• Common side effects and who is not a candidate stated where results are shown.
• Before-and-after photos are your own patients’, consented, labeled with sessions and add-ons (16 CFR 255.2).
• Typical results disclosed when a showcased result is not typical (16 CFR 255.2(b)).
• Infection control claims (new cartridge per session) are your written practice.
• Operator titles and credentials accurate and checked against your state’s rules.

How we help

We build service pages, treatment menus and before-and-after galleries for med spas and dermatology practices, with device, result and combination claims checked against the sources above: website design, healthcare SEO for local treatment searches, and lead generation campaigns. We do not give legal opinions on device status or state scope-of-practice rules, and we are not a law firm. Related guides: med spa SEO, cryotherapy and red light marketing claims and Google Ads for med spas.

Sources

• 21 CFR 878.4430: Microneedling device for aesthetic use
• 21 CFR 807.97: Misbranding by reference to premarket notification
• 21 CFR 807.39: Misbranding by reference to establishment registration
• FDA guidance: Regulatory Considerations for Microneedling Products (November 2020)
• FDA: Microneedling Devices
• FDA consumer update: Microneedling Devices: Getting to the Point on Benefits, Risks and Safety
• FDA safety communication: Potential Risks with Certain Uses of Radiofrequency (RF) Microneedling (October 15, 2025)
• 15 USC 52: Dissemination of false advertisements
• 15 USC 55: Additional definitions
• 16 CFR 255: Guides concerning use of endorsements and testimonials in advertising

More in Cash-pay, aesthetic and wellness care